Dess M, Noce A, Dawood KF, Galli F, Taccone-Gallucci M, Fabrini R et al
Use U-100 insulin syringes exclusively for GLP-1 subcutaneous delivery
These gaps leave employees either paying out of pocket or forgoing treatment while employers absorb the downstream costs of unmanaged chronic disease
And importantly, if unintended weight loss occurs in a lean patient, we stop or lower the dose
Semaglutide acts as a glucagon-like peptide-1 (GLP-1 receptor agonist) that occupies GLP-1 receptors and mimics the action of human glucagon-like peptide-1 hormone
The combined expertise of Stevanato Group and SHL Medical supports complex drug delivery projects, offering a practical, de-risked approach for pharmaceutical partners